Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Paramedic Initiated Lisinopril For Acute Stroke Treatment (PIL-FAST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01066572
Recruitment Status : Completed
First Posted : February 10, 2010
Last Update Posted : March 30, 2017
North East Ambulance Service NHS Foundation Trust
Northumbria Healthcare NHS Foundation Trust
Information provided by (Responsible Party):
Newcastle-upon-Tyne Hospitals NHS Trust

Brief Summary:
This study aims to investigate the use of lisinopril to lower blood pressure in stroke patients, pre-hospital, by research-trained paramedics.

Condition or disease Intervention/treatment Phase
Stroke Drug: Lisinopril Drug: Placebo Phase 1

Detailed Description:

High blood pressure immediately following stroke is common and related to poorer stroke functional outcome and death. Although treatment of high blood pressure is well established for thre prevention of stroke, it is unclear if high blood pressure observed immediately after stroke should be lowered.

Several previous clinical trials have lowered blood pressure in acute stroke but this has not resulted in improved stroke outcome. One reason for this may be because treatment was started too late after stroke occurred. There is rapid progression of brain injury following stroke and any stroke treatment may need to be started very early to have a beneficial effect. Previous trials started blood pressure lowering after patients arrived at hospital and this was usually a significant time after stroke occurred.

The earliest time after stroke that blood pressure treatment could be started is during contact with the emergency medical services (paramedics). This research study is a pilot double blind randomised controlled trial of paramedic initiated blood pressure treatment for patients with high blood pressure immediately after stroke.

Patients with high blood pressure and suspected acute stroke will be identified and offered the opportunity to participate in the study by research trained paramedics from the North East Ambulance Service NHS Trust. Patients who agree to participate in the study will receive either lisinopril (a common blood pressure lowering medication) or 'dummy' (placebo) treatments for seven days. The first dose of medication will be given by the paramedic in the ambulance. Subsequent tablets will be given in hospital. The effects of treatment will be monitored by measuring blood pressure, neurological outcome and adverse events.

All aspects of study feasibility including recruitment rates and compliance with data collection will be recorded. The study will run for one year and recruit 60 patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Paramedic Initiated Lisinopril For Acute Stroke Treatment: a Pilot Randomised Controlled Trial
Study Start Date : October 2010
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Lisinopril

Arm Intervention/treatment
Experimental: Lisinopril
Drug: Lisinopril
5-10 mg Lisinopril per day for seven days, depending on blood pressure.
Other Name: ACE inhibitor

Placebo Comparator: Placebo
Placebo Comparator
Drug: Placebo
Matched placebo; identical tablets to Lisinopril.
Other Name: Dummy drug

Primary Outcome Measures :
  1. Number of participants enrolled per month [ Time Frame: 1 year ]
    The primary outcome measure is the number of participants enrolled in the study per month.

Secondary Outcome Measures :
  1. Proportion fulfilling eligibility criteria [ Time Frame: 1 year ]
    The proportion of suspected acute stroke patients admitted to research sites during the trial duration who fulfilled the study eligibility criteria

  2. Proportion attended by research trained paramedic [ Time Frame: 1 year ]
    The proportion of study eligible patients attended by a research trained paramedic

  3. Proportion enrolled by research trained paramedic [ Time Frame: 1 year ]
    The proportion of study eligible patients enrolled into the study by a researc trained paramedic

  4. Proportion approached but not enrolled [ Time Frame: 1 year ]
    The proportion of study eligible patients approached about the research study but not enrolled, and the reasons for non-enrolment, where possible.

  5. Additional time spent on scene [ Time Frame: 1 year ]
    The additional time spent on scene by research trained paramedics to enrol a participant into the study.

  6. Paramedic compliance [ Time Frame: 1 year ]
    Paramedic compliance with study data collection.

  7. Hospital staff compliance [ Time Frame: 1 year ]
    Hospital staff compliance with study medication administration and data collection.

  8. Proportion completing study medication [ Time Frame: 1 year ]
    The proportion of study participants with confirmed stroke who complete seven days of study medication.

  9. Clinical outcome measures [ Time Frame: 1 year ]
    Clinical outcome measures are blood pressure, neurological score, dependency score and renal function.

  10. Adverse events [ Time Frame: 1 year ]
    Adverse events in control and intervention groups during the study.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults ≥ 40 years old
  • New unilateral arm weakness thought to be due to acute stroke within 3 hours of symptom onset
  • Hypertension as defined by systolic BP >160mm Hg on two consecutive seated or lying readings taken 5 - 10 minutes apart
  • Conscious (eyes open spontaneously ie "A" on Alert, Voice, Pain, Unresponsive (AVPU) scale)
  • Patient being transported to a PIL-FAST trial site (i.e. Royal Victoria Infirmary, North Tyneside General Hospital and Wansbeck General Hospital)
  • Verbal consent obtained from participant or next of kin

Exclusion criteria:

  • Age < 40 years
  • Females who are pregnant, lactating or at risk of pregnancy (i.e. who are not surgically sterile or at least 1 year post last menstrual period). Females < 56 years of age consented by a relative will be excluded as menstrual history may be unknown.
  • Any presentation of suspected stroke without unilateral arm weakness
  • Cannot establish that stroke onset time (i.e. when patient was last seen well without symptoms) was within the last 3 hours
  • Systolic BP < 160mm Hg
  • Reduced level of consciousness (below "A" on AVPU scale)
  • Patient not being transported to PIL-FAST trial site
  • Absence of participant or next of kin consent
  • Known to be taking ACE-inhibitor or Angiotensin II Receptor Blocker medication already
  • Known sensitivity to lisinopril or other ACE-inhibitor medication
  • Pulse > 120 beats per minute
  • Seizure activity in this illness episode (witnessed or history)
  • Hypoglycaemia (blood glucose < 3.5 mmols/l)
  • Cannot walk independently prior to stroke (walking stick / frame is allowed)
  • Obvious understanding or memory problems when next of kin is absent
  • Significant head trauma or brain surgery in the last 3 months
  • Known renal failure
  • Known liver failure (or currently jaundiced)
  • Uncontrolled heart failure (breathlessness at rest)
  • Receiving palliative care for known malignancy
  • Currently enrolled in a clinical trial assessing a study drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01066572

Layout table for location information
United Kingdom
Wansbeck General Hospital
Ashington, Northumberland, United Kingdom, NE63 9JJ
Royal Victoria Infirmary, Queen Victoria Road
Newcastle upon Tyne, Tyne and Wear, United Kingdom, NE1 4LP
North East Ambulance Service NHS Trust
Newcastle upon Tyne, Tyne and Wear, United Kingdom, NE15 8NY
North Tyneside General Hospital
North Shields, Tyne and Wear, United Kingdom, NE29 8NH
Sponsors and Collaborators
Newcastle-upon-Tyne Hospitals NHS Trust
North East Ambulance Service NHS Foundation Trust
Northumbria Healthcare NHS Foundation Trust
Layout table for investigator information
Principal Investigator: Christopher Price Northumbria Healthcare NHS Foundation Trust
Principal Investigator: Anand Dixit Newcastle-upon-Tyne Hospitals NHS Trust
Principal Investigator: Ann Fox North East Ambulance Service NHS Foundation Trust
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Newcastle-upon-Tyne Hospitals NHS Trust Identifier: NCT01066572    
Other Study ID Numbers: RP-PG-0606-1241
First Posted: February 10, 2010    Key Record Dates
Last Update Posted: March 30, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: No IPD were shared, nor will be, from this trial.
Additional relevant MeSH terms:
Layout table for MeSH terms
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents
Cardiotonic Agents
Protective Agents
Physiological Effects of Drugs